Skip to main content

Table 4 Adverse events - incidence and grading according to CTCAE v 4.03

From: Retrospective review of safety and efficacy of programmed cell death-1 inhibitors in refractory high grade gliomas

Toxicity Overall incidence, no. (%) Grade 1 and 2, no. (%) Grade 3 and 4, no. (%)
Hyperglycemia 19 (79) 19 (79)  
Fatigue 19 (79) 18 (75) 1 (4)
Thrombocytopenia 12 (50) 12 (50)  
Headache 11 (46) 10 (43) 1 (4)
Nausea 10 (42) 9 (38) 1 (4)
Leukopenia 9 (38) 9 (38)  
ALT elevations 8 (33) 8 (33)  
AST elevations 7 (29) 7 (29)  
Bilirubin elevations 5 (21) 5 (21)  
Neutropenia 5 (21) 5 (21)  
Anemia 5 (21) 4 (17) 1 (4)
Seizures 5 (21) 4 (17) 1 (4)
Vomiting 5 (21) 4 (17) 1 (4)
Thyroid toxicity 4 (17) 4 (17)  
Diarrhea 4 (17) 4 (17)  
Myalgias/Arthralgias 3 (13) 3 (13)  
Rash 2 (8) 2 (8)  
Pyrexia 2 (8) 2 (8)  
Lipase 1 (4) 1 (4)  
Amylase 1 (4) 1 (4)  
Mucositis 1 (4) 1 (4)